VKTX Latest Press Releases

-- April 10, 2026 --

Viking Therapeutics to Participate at Upcoming Investor Conferences PRNewswire 7:30 AM

-- March 26, 2026 --

Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735 PRNewswire 7:05 AM

-- March 5, 2026 --

Viking Therapeutics to Participate at Upcoming Investor Conferences PRNewswire 4:03 PM

-- February 11, 2026 --

Viking Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update PRNewswire 4:16 PM

-- February 4, 2026 --

Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2025 on February 11, 2026 PRNewswire 4:05 PM

-- January 12, 2026 --

Viking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal Obesity PRNewswire 7:00 AM

-- January 8, 2026 --

Viking Therapeutics Announces Completion of Enrollment in Maintenance Dosing Clinical Trial of VK2735 in Obesity PRNewswire 7:00 AM

-- January 7, 2026 --

Viking Therapeutics Announces Appointment of Neil Aubuchon as Chief Commercial Officer PRNewswire 7:00 AM

-- January 5, 2026 --

Viking Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference PRNewswire 4:03 PM

-- November 25, 2025 --

Viking Therapeutics to Participate at the Piper Sandler 37th Annual Healthcare Conference PRNewswire 4:05 PM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software